Several plasminogen activators (PAs) have been found effective in treating different
thromboembolic diseases. However, administration of conventional thrombolytic therapy is …

Intravascular administration of plasminogen activators is a clinically important thrombolytic
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …

Various plasminogen activators have been routinely used for the treatment of thrombotic
diseases. However, these agents possess various problems eg short half life and other …

This handbook (55 chapters) provides a comprehensive roadmap of basic research in
nanomedicine as well as clinical applications. However, unlike other texts in nanomedicine …

Predicting the size and toxicity of chitosan/streptokinase nanoparticles at various values of
processing parameters was the aim of this study. For the first time, a comprehensive model …

Recombinant tissue plasminogen activator (rtPA) was encapsulated in thermosensitive
magnetic liposome (TML) prepared from 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine …

In this study, the enzyme streptokinase (thrombolysis agent) and chitosan (Cs) nanoparticles
were prepared by self-assembly. Using experimental design, chitosan concentration …

Reflecting the breadth of the field from research to manufacturing, Nanoscience and
Nanoengineering: Advances and Applications delivers an in-depth survey of emerging, high …

Once thrombi have formed as part of the pathology defining myocardial infarction, ischemic
stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the …

Streptokinase is being successfully used as a thrombolytic agent for restoring the blood flow
following thromboembolism and myocardial infarction. However, high immunogenicity of the …